HUE028811T2 - Kristályos pirazol-származék - Google Patents
Kristályos pirazol-származék Download PDFInfo
- Publication number
- HUE028811T2 HUE028811T2 HUE05708783A HUE05708783A HUE028811T2 HU E028811 T2 HUE028811 T2 HU E028811T2 HU E05708783 A HUE05708783 A HU E05708783A HU E05708783 A HUE05708783 A HU E05708783A HU E028811 T2 HUE028811 T2 HU E028811T2
- Authority
- HU
- Hungary
- Prior art keywords
- mixture
- temperature
- moles
- crystalline
- crystals
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 109
- 239000013078 crystal Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000002904 solvent Substances 0.000 claims description 42
- 239000000725 suspension Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 14
- -1 sulfur isopropoxide Chemical compound 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- 239000004922 lacquer Substances 0.000 claims 3
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims 2
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000000571 coke Substances 0.000 claims 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000002054 inoculum Substances 0.000 claims 1
- 230000002262 irrigation Effects 0.000 claims 1
- 238000003973 irrigation Methods 0.000 claims 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000004317 sodium nitrate Substances 0.000 claims 1
- 235000010344 sodium nitrate Nutrition 0.000 claims 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims 1
- 229910001948 sodium oxide Inorganic materials 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 40
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 39
- TTZNQDOUNXBMJV-UHFFFAOYSA-N mavacoxib Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 TTZNQDOUNXBMJV-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- 238000000634 powder X-ray diffraction Methods 0.000 description 11
- 150000004703 alkoxides Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 238000001144 powder X-ray diffraction data Methods 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 7
- IKEURONJLPUALY-UHFFFAOYSA-N 4-hydrazinylbenzenesulfonamide;hydron;chloride Chemical compound [Cl-].NS(=O)(=O)C1=CC=C(N[NH3+])C=C1 IKEURONJLPUALY-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 3
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 3
- AZVCGYPLLBEUNV-UHFFFAOYSA-N lithium;ethanolate Chemical compound [Li+].CC[O-] AZVCGYPLLBEUNV-UHFFFAOYSA-N 0.000 description 3
- HAUKUGBTJXWQMF-UHFFFAOYSA-N lithium;propan-2-olate Chemical compound [Li+].CC(C)[O-] HAUKUGBTJXWQMF-UHFFFAOYSA-N 0.000 description 3
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 3
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- WQKGAJDYBZOFSR-UHFFFAOYSA-N potassium;propan-2-olate Chemical compound [K+].CC(C)[O-] WQKGAJDYBZOFSR-UHFFFAOYSA-N 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KNWHPVXBSDQDAZ-UHFFFAOYSA-N 2-(3-phenyl-1h-pyrazol-5-yl)benzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=NNC(C=2C=CC=CC=2)=C1 KNWHPVXBSDQDAZ-UHFFFAOYSA-N 0.000 description 2
- KEZLARPKXOHKJS-UHFFFAOYSA-N 4,4,4-trifluoro-1-(4-fluorophenyl)butane-1,3-dione Chemical compound FC1=CC=C(C(=O)CC(=O)C(F)(F)F)C=C1 KEZLARPKXOHKJS-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000012777 commercial manufacturing Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W16/00—Network planning, e.g. coverage or traffic planning tools; Network deployment, e.g. resource partitioning or cells structures
- H04W16/18—Network planning tools
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W24/00—Supervisory, monitoring or testing arrangements
- H04W24/02—Arrangements for optimising operational condition
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (7)
- SZABADALMI igénypontok 1. A 4-{S-f441mri\Mî^B'<irMîM«mïetiO~H-l-pi)raxoLî-i{j-bertzolsxulfbnamid ? kristályom»' alakja, aroelyöök por-tömgensagár diffiuteiés mhnázaia szögben kifejezve (.*. 0,1 A 2-theta « 14.02 IS,92 21,32,21,9° ss 25,7° értékeknél m«M csőcsokat, CuKut röntgensugarat alkalmazva (hullámhossz ~ 1.54Dö Angstrom).
- 2. Eljárás a 3. ibrás bemutatott 4-[544''Eaorf^:ll)~3-(tiilkiornietll:)-îï!~|>lrazol~l-11)--batzolszulfónamid II kmtályalak átalakítására az I . 'igénypont szerinti k ristá ly alakká, amely az alábbi lépeseket tartalmazza; (a) B kristályalakjának szuszpenzióját: elkeverjük egy megfelelő oldószerben, ahol a hatóanyag oldfmtösága. nagyobb mim img/mL és alacsonyabb mini 8(H) rog/roL, Ö-ÓtAü hőmérsékleten; (b) a sznszpenzlét Q-Mp€ hőmérsékleten 24-72 óráig: keverjük; és (ο) Összegypjijüfe m I kristálya lakokat.
- 3. Eljárás 4-[5«(4-íl:uotfemi)*3-(trlf1«omtetil>* 1 ri-pírazol- l»iÍj^feo«zofeul:fbfta«ná l.l krislályafekjának átalakítására: az I. igénypont szerinti kristályaink ká, amely az alábbi lépéseket tártaim azzá: (a.) a ÏI kristályaiakoi feloldjuk egy vízzel elegyedő Oldószerben, ahol a II krMályalák oldhatósága nagyobb mait 2 ingóul., i 0-60°C hőmérsékleten; (b) a vegyületeí víz hozzáadásával kicsapjuk; (c) a íi) lépésben kapott szuszpenziőt 2-72 óráig keverjük i 5 ~4S°G hőmérsékleten; és d) összegyűjtjük az I krisiályak-kokm.
- 4. Az I, Igénypont szerinti telályafekot fariaímazö gyógyászati készíöaény, ahol a készítmény száraz, szilárd dózlsfbrmtt. 5. A 4, igénypont szerinti készítmény, amely umalmaz továbbá egy gyógyászatilag elfogadható hordozóanyagot vagy segédanyagot, ó. Egy 1. igénypont szerinti kristályalak vagy egy 4. igénypont szerinti készítmény, egy állal gyulladásos állapotának megelőzésére vagy kezelésére szolgáló gyógyszer előállításában való alkalmazásra, ?, A b. igénypont szerinti alkalmazásra szolgáló vegyölet, ahol az állat szarvasmarha, juh, kecske, ló, sertés, madár, macska, kutya és ember köréből választott, b, Eljárás az 1. Igénypont szerinti kristályalak előállítására, amely az alábbi lépésekből ált: (a) 1 mol 4-.0»oraeemfenoríra számított 1,0-1,6 mol alkibíriiluoracesáttn. I moi 4-llnomcetofenoma számított 1,0-1,5 mo1 íém-alkezitiot, és Ismert mmtxyiségíi 4·Cl^oraeetofenoHt vegyítünk egy keverékké; íb) az (à) lépésben kapót! keveréket kombináljuk i mól A-Pnoraeetoienimra számított 415-:1 „24$ ml via, ! mol 4-iluoraeetofenottra számított 1,1-2,O mol tömény sósav, 1 mo! 4-flooravetof4poHta számított feöl 4~szolfoízásoldo&oyhkteoo sósav, és olyan mennyiségű megfelelő oldószer efegyévek hogy á keverék teljes ol4ós2en»eonyi$égn SSb-íéóO ml legye» I met 4-booracetofenonra számítva; (e) 4-15-(4-f]uorrenr;}-3-í;TÍfleotmetjÍ}-illl:-pirazol-i4r!4xetzoisait!fo»át»kl 1 kristály-alakjának 4-lluüraostsfenonon alapuló oltási monayiségét adjuk a keverékhez: 14) összegyűjtjük az ! kristályaiakpk&í. 9, A 8, igénypont szerinti eljárás, amely az a.) lépésben tartalmazza továbbá 1 mol 4-riuömeetefeímara számított legfeljebb I3S0 mimegfelelő oldószer hozzáadását a keverékhez.
- 10, Eg}' 8. igénypont szeriMi eijázás zz i. jgénypöíd szerinti 'kristályai előállítására, amely tíz alábbi lépésekből áll; (a) 5 tnol 4·íluoraeetofenoma számított 1,2-1,45 mól aikil-mrioomeetitöt, 1 moi 4-finoracetofenonra számított 1,1-1.35 inni fem-alkoxldot, és Ismeri mennyiségű 4-ffeoracstofen:ont yggyittmk egy keverékké; (b) az (a) lépésben kapott keveréket kombmájjok i mól 4-ritmmeetofenöara számított hSÖ-870 ml viz, 1 möl 4-fiuoracetoíenonra szintiteS 1,2-1,7 mól tömény sósav, 1 mól 4-floomoeMéno«ra· számított 0,0-1,1 mól 4“SZ«lfettánt iífeiénil:5i4razitt sósav, és olyan mennyiségű, megfelelő oldószer elegyével, bogy a keverek teljes oMószermeanyisége ÓOÍMOOO ml legyen I. mól 4-rinoraeetofenonra számítva; te) 4-j:S-(4--ri:uorfenil)-3-(lril:btormetii3-líl-pirazoi- i-ilj-beazolsznl&namsé 1 fcristályaiakjánsk 4-riooracelofénottott alapélé oltást soeooyiségét adjak a keverékhez; (é) összegyűjtjük az 1 feristályalakokal 11, À 8. vagy 10. igénypont szerinti eljárás, aboi a tém-alkoxid nátriem-melozlá, nátrium-etoxtd, nát-rlnm-lzopí'Opozid, nátrinm-lerc-buíoziá, tllmm-meíboxide, li'tium-etoxid. íírium-izopropoxid, itinm-tem-btttoxiá, kálinm-mélozitl, kálmm-etoxM, kálhonrizopropoxiű, kábum-tem-bntozid, és ezek keverékeinek körébe! választott. '12. Λ S. Igénypont szerinti eljárás, amely az fa) lépés után tartalmaz egy további lépést, amelyben, a keveréket szobahőmérséklet lóié, legfeljebb a refluxhőmérsékletig melegítjük amíg a reakció végbe tmm megy. 1 A. A 12. igénypont szerinti eljárás., amely a melegítési lépést követően tartalmazza: továbbá a keverék lekötését -ő-AlFC Irémérrékletre, 14. A 8„ vagy 10. igénypont szerinti eljárás, ahol a (b) lépés tartafoazsza 8 keverék hozzáadását víz, sósav és l-szoUbnamidofemlhidrazsp sósav elegyéhez.. 15. A 8.. vagy 1 0. Igénypont szerinti eljárás, ahol a <b> lépésben szereplő oldószer alkohol. lő. A Igénypont szerinti eljárás, amely a (b) lépés mars tartalmaz egy további lépést, amelyben a keveréket szobahőmérséklet fölé, legfeljebb a reffe hőmérsékletig melegítjük, amig a reakció végbe nem megy. 1Î, A lő. Igénypont szerből eljárás,: amely a melegítési lépési kővető«« tamltaazza továbbá a keverék átabsllzálását szobahőmérséklet és 7t,$°C közötti hőmérsékleten. IS, A B, vagy 10. Igénypont szerinti eljárás, ahol az oltási mennyiség 0,0001 · 50 tömegéi. 19, A 8. igénypont szerinti eljárás, amely a (e) lépés otán tartalmaz egy további lépést, amelyben a keveréket 40-71 .ö^C hőmérsékletre melegítjük I -1 ö óráig, 20, A 19. igénypont szerinti eljárás, amely a melegilési lépést kővetően tartalmazza továbbá a kevesek lehűtéséi ~3-2Ö*€ hőmérsékletre.
- 21, A i vagy ük igénypont szerinti eljárás, amely a (c) lépést követően tartalmazza továbbá a keverék szűrését és: az ! kristálvatakn kristályok mosását egy megfelelő oldószerrel, vízzel vagy ezek keverékével,
- 22, A I. Igénypont szerinti eljárás, amely a (dj lépést kővetően tartalmazza, továbbá íré 1 kriréélyalaku kristályok szárítását 15-8ÍPG hőmérsékleten.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55846904P | 2004-04-01 | 2004-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028811T2 true HUE028811T2 (hu) | 2017-01-30 |
Family
ID=34961629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE05708783A HUE028811T2 (hu) | 2004-04-01 | 2005-03-21 | Kristályos pirazol-származék |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7652149B2 (hu) |
| EP (1) | EP1742922B1 (hu) |
| JP (1) | JP4177883B2 (hu) |
| KR (1) | KR100820511B1 (hu) |
| CN (1) | CN1938276B (hu) |
| AR (1) | AR048449A1 (hu) |
| AU (1) | AU2005227745C1 (hu) |
| BR (1) | BRPI0509506A8 (hu) |
| CA (1) | CA2562104C (hu) |
| DK (1) | DK1742922T3 (hu) |
| EA (1) | EA008697B1 (hu) |
| ES (1) | ES2565409T3 (hu) |
| HU (1) | HUE028811T2 (hu) |
| IL (1) | IL177711A0 (hu) |
| MA (1) | MA28494B1 (hu) |
| NO (1) | NO20064986L (hu) |
| NZ (1) | NZ550907A (hu) |
| PL (1) | PL1742922T3 (hu) |
| SI (1) | SI1742922T1 (hu) |
| TN (1) | TNSN06313A1 (hu) |
| TW (1) | TW200536816A (hu) |
| UA (1) | UA84455C2 (hu) |
| WO (1) | WO2005095349A1 (hu) |
| ZA (1) | ZA200607154B (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005095349A1 (en) * | 2004-04-01 | 2005-10-13 | Pharmacia & Upjohn Company Llc | Crystalline pyrazole derivative |
| JP5396085B2 (ja) | 2005-12-14 | 2014-01-22 | マクテシム・ケミカル・ワークス・リミテツド | 5−アミノ−1−[2,6−ジクロロ−4−(トリフルオロメチル)フェニル]−4−[(トリフルオロメチル)スルフィニル]−1h−ピラゾール−3−カルボニトリルの多形および非晶形 |
| UA110598C2 (uk) | 2006-11-10 | 2016-01-25 | Басф Се | Спосіб одержання кристалічної модифікації фіпронілу |
| KR101540122B1 (ko) | 2006-11-10 | 2015-07-28 | 바스프 에스이 | 피프로닐의 결정질 변형물 |
| EA017180B1 (ru) | 2006-11-10 | 2012-10-30 | Басф Се | Новая кристаллическая модификация фипронила и ее применение |
| JP2017081860A (ja) * | 2015-10-29 | 2017-05-18 | 株式会社トクヤマ | セレコキシブの製造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0461930B1 (en) | 1990-06-15 | 1995-09-13 | Merck & Co. Inc. | A crystallization method to improve crystal structure and size |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US6492411B1 (en) * | 1993-11-30 | 2002-12-10 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| BR9611047A (pt) | 1995-10-17 | 2000-03-08 | Searle & Co | Processo de deteção de ciclo oxigenase-2 |
| US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| US6221153B1 (en) | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
| US6787154B2 (en) | 1998-10-20 | 2004-09-07 | Salvatore Albani | Artificial antigen presenting cells |
| SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| TR200001872A3 (tr) * | 2000-06-26 | 2002-01-21 | Fako Ilaclari A.S | 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem. |
| WO2005095349A1 (en) * | 2004-04-01 | 2005-10-13 | Pharmacia & Upjohn Company Llc | Crystalline pyrazole derivative |
-
2005
- 2005-03-21 WO PCT/IB2005/000735 patent/WO2005095349A1/en not_active Ceased
- 2005-03-21 BR BRPI0509506A patent/BRPI0509506A8/pt not_active Application Discontinuation
- 2005-03-21 EA EA200601601A patent/EA008697B1/ru not_active IP Right Cessation
- 2005-03-21 DK DK05708783.5T patent/DK1742922T3/en active
- 2005-03-21 ES ES05708783.5T patent/ES2565409T3/es not_active Expired - Lifetime
- 2005-03-21 SI SI200532061A patent/SI1742922T1/sl unknown
- 2005-03-21 JP JP2007505649A patent/JP4177883B2/ja not_active Expired - Lifetime
- 2005-03-21 HU HUE05708783A patent/HUE028811T2/hu unknown
- 2005-03-21 CN CN2005800098297A patent/CN1938276B/zh not_active Expired - Lifetime
- 2005-03-21 NZ NZ550907A patent/NZ550907A/en not_active IP Right Cessation
- 2005-03-21 PL PL05708783T patent/PL1742922T3/pl unknown
- 2005-03-21 EP EP05708783.5A patent/EP1742922B1/en not_active Expired - Lifetime
- 2005-03-21 AU AU2005227745A patent/AU2005227745C1/en not_active Expired
- 2005-03-21 UA UAA200610388A patent/UA84455C2/ru unknown
- 2005-03-21 KR KR1020067020308A patent/KR100820511B1/ko not_active Expired - Fee Related
- 2005-03-21 CA CA2562104A patent/CA2562104C/en not_active Expired - Lifetime
- 2005-03-30 AR ARP050101229A patent/AR048449A1/es not_active Application Discontinuation
- 2005-03-31 TW TW094110251A patent/TW200536816A/zh unknown
- 2005-03-31 US US11/095,381 patent/US7652149B2/en active Active
-
2006
- 2006-08-27 IL IL177711A patent/IL177711A0/en unknown
- 2006-08-28 ZA ZA200607154A patent/ZA200607154B/en unknown
- 2006-09-29 TN TNP2006000313A patent/TNSN06313A1/fr unknown
- 2006-09-29 MA MA29353A patent/MA28494B1/fr unknown
- 2006-10-31 NO NO20064986A patent/NO20064986L/no unknown
-
2009
- 2009-12-18 US US12/641,404 patent/US20100093820A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI345562B (en) | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof | |
| JP2017206516A (ja) | プリドピジン塩酸塩の新規な多形形態 | |
| HUE029738T2 (hu) | 4-[2-[[5-Metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etil]morfolin-hidroklorid polimorfok és szolvátok | |
| HUE026408T2 (hu) | Dabigatran-etexilát-biszmezilát só, szilárd állapotú formái és eljárás elõállításukra | |
| US20100093820A1 (en) | Crystalline pyrazoles | |
| Zhang et al. | Hydrates and Solvates of Acotiamide Hydrochloride: Crystallization, Structure, Stability, and Solubility | |
| MX2013001559A (es) | Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1 h-pirazol-3-il]oxi]etil]morfolina. | |
| JP7326295B2 (ja) | オキサゾール化合物結晶 | |
| EP2626355B1 (en) | Process for the preparation of nilotinib hydrochloride | |
| AU2021428932A1 (en) | Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof | |
| JP7113542B2 (ja) | 複素環式化合物及びその医学的応用 | |
| KR101663335B1 (ko) | 6-(1-메틸-1h-피라졸-4-일)-2-{3-[5-(2-모르폴린-4-일-에톡시)-피리미딘-2-일]-벤질}-2h-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법 | |
| JP6761564B2 (ja) | ナトリウム・グルコース共輸送体2阻害薬のl−プロリン化合物、およびl−プロリン化合物の一水和物および結晶 | |
| JP7322151B2 (ja) | 医薬化合物、その製造方法、及び薬剤としての使用 | |
| EP3684770B1 (en) | Salts and solid state forms of larotrectinib | |
| MXPA06011120A (en) | Crystalline pyrazole derivative | |
| CN113166172B (zh) | 呋喃并嘧啶化合物的盐和晶型及其药物用途 | |
| JP2021530550A (ja) | ブロモドメイン阻害剤の合成方法 | |
| HK1099755B (en) | Crystalline pyrazole derivative | |
| JP7033662B2 (ja) | 大規模なトリミドンの調製方法 | |
| CN117836271A (zh) | 苯基吡咯氨基胍的盐和苯基吡咯氨基胍鎓盐的多晶型物 | |
| EA046293B1 (ru) | Способ получения ингибитора бромодомена | |
| HK1238636A1 (en) | Sodium salt of uric acid transporter inhibitor and crystalline form thereof | |
| UA115741U (xx) | СПОСІБ ОДЕРЖАННЯ 3H-ТІАЗОЛО[4,3b]БЕНЗО[g]ХІНАЗОЛІН-1,11-ДІОНУ |